![](https://www.just-food.com/wp-content/uploads/sites/28/2021/04/2015-12-18-23-00-baby_fill_90-1.jpg)
Biostime International Holdings, the Hong Kong-listed infant formula maker, has reported higher nine-month revenue, as sales from vitamins arm Swisse offset pressure on its formula business.
The company posted revenue of CNY4.68bn (US$675.9m) for the nine months to the end of September, up from CNY4.49bn a year earlier.
However, Biostime said revenue from its baby care and nutrition division fell 3.3% amid a “highly competitive” infant formula market in China.
Biostime said the lower revenue from the division was “mainly attributable” to a decline in sales of its “mid-tier” Adimil infant formula brand. By contrast, revenue from the company’s Biostime-branded formula rose 8.8%.
Citing Nielsen data, Biostime said the company accounted for 6% of infant formula sales in China during the period, compared to 5.9% a year earlier.
Revenue from Swisse, which Biostime acquired in September 2015, rose 13.3%.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
![](/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBiostime did not provide figures on profits for the nine-month period.